Title | Ovarian Cancer 3 [electronic resource] / edited by Frank Sharp, Peter Mason, Tony Blackett, Jonathan Berek |
---|---|
Imprint | Boston, MA : Springer US, 1994 |
Connect to | http://dx.doi.org/10.1007/978-1-4757-0136-4 |
Descript | 390 p. 76 illus. online resource |
One Genetics Of Ovarian Cancer -- 1 The genetic epidemiology of ovarian cancer -- 2 Genetic epidemiology of familial ovarian cancer in Utah -- 3 Isolating tumour suppressor genes relevant to ovarian carcinoma โ the role of loss of heterozygosity -- 4 The BRCAl gene in sporadic breast and ovarian cancer -- 5 Allele losses on chromosome 17 in ovarian tumours -- 6 Cloning and molecular characterization of monoclonal antibody-defined ovarian tumour antigens -- 7 New insights into the genetics of human ovarian epithelial tumor development -- Two Tumour Biology -- 8 Molecular and biological factors in the pathogenesis of ovarian cancer -- 9 Cytokines and ovarian cancer -- 10 Growth factors and receptors in ovarian cancer -- 11 Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-? -- 12 TNF, LT AND IL-1 natural inhibitors (soluble receptors and receptor antagonists) in women with ovarian cancer -- 13 Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid -- Three Early Ovarian Cancer and Borderline Tumours -- 14 Update on early ovarian cancer and cancer developing in benign ovarian tumors -- 15 Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer -- 16 Human ovarian surface epithelium: growth patterns and differentiation -- 17 Management of low malignant potential ovarian tumors -- 18 Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment? -- 19 Complementary and coordinate markers for detection of epithelial ovarian cancers -- Four Chemotherapy Radiotherapy and Ethics -- 20 Chemotherapy options in ovarian carcinoma โ A dose intensity perspective -- 21 Drug resistance in ovarian cancer and potential for its reversal -- 22 Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer -- 23 The European-Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion -- 24 Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second look laparotomy -- 25 Matrix metalloproteinases and their role in ovarian cancer -- 26 Signal transduction therapy: a new paradigm -- 27 Radiotherapy as salvage or consolidation therapy in advanced epithelial ovarian cancer -- 28 Ethical decision making in the care of seriously ill and dying patients Theory and practice -- Five Immunotherapy and Gene Therapy -- 29 Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF-?/anti-Fas antibody and chemotherapeutic drugs or toxins -- 30 Potential for immunotherapy: PEM as a target antigen -- 31 Ovarian tumour reactive cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins Muc-1 -- 32 Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells -- 33 Active specific immunotherapy (ASI). An immunological approach to ovarian cancer treatment -- 34 Antibody targeting of ovarian cancer: recombinant single-chain fragments and the role of internalization -- 35 Carcinoembryonic antigen (CEA) promoter directed tissue specific gene expression in CEA expressing tumour cells -- Six Conclusions and Recommendations -- 36 Conclusions and recommendations